CymaBay Therapeutics, Inc.
NASDAQ:CBAY
Overview | Financials
Company Name | CymaBay Therapeutics, Inc. |
Symbol | CBAY |
Currency | USD |
Price | 32.48 |
Market Cap | 3,728,216,800 |
Dividend Yield | 0% |
52-week-range | 7.261 - 32.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sujal A. Shah |
Website | https://www.cymabay.com |
An error occurred while fetching data.
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD